Drug Profile


Alternative Names: DF01

Latest Information Update: 08 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dilafor
  • Developer Dilafor; Lees Pharmaceutical Holdings
  • Class Glycosaminoglycans; Low molecular weight heparins
  • Mechanism of Action Muscle protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Dystocia

Most Recent Events

  • 21 Jan 2017 Phase-II clinical trials in Dystocia (Adjunctive treatment) in Finland (IV) (EudraCT2016-002118-40)
  • 01 Dec 2016 Phase-II clinical trials in Dystocia (Adjunctive treatment) in Sweden (IV) (NCT03001193)
  • 25 Jul 2015 Dilafor completes a phase I trial in Dystocia (In volunteers) in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top